

Published in final edited form as:

J Subst Abuse Treat. 2015 January ; 48(1): 96–103. doi:10.1016/j.jsat.2014.07.014.

An exploratory study of the combined effects of orally administered methylphenidate and delta-9-tetrahydrocannabinol (THC) on cardiovascular function, subjective effects, and performance in healthy adults

Scott H. Kollins, Ph.D.^{a,*}, Erin N. Schoenfelder, Ph.D.^b, Joseph S. English, M.S.^a, Alex Holdaway^a, Elizabeth Van Voorhees, Ph.D.^c, Benjamin R. O'Brien^a, Rachel Dew, M.D.^a, and Allan K. Chrisman, M.D.^a

^aDepartment of Psychiatry and Behavioral Science, Duke University School of Medicine, Durham, NC

^bDepartment of Psychiatry; Seattle Children's Hospital, Seattle, WA

^cDurham VA Medical Center, Durham, NC

Abstract

Methylphenidate (MPH) is commonly prescribed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), and is often used illicitly by young adults. Illicit users often coadminister MPH with marijuana. Little is known about physiologic and subjective effects of these substances used in combination. In this double-blind, cross-over experiment, sixteen healthy adult subjects free from psychiatric illness (including ADHD) and reporting modest levels of marijuana use participated in 6 experimental sessions wherein all combinations of placebo or 10 mg oral doses of delta-9-tetrahydrocannabinol (THC); and 0 mg, 10 mg and 40 mg of MPH were administered. Sessions were separated by at least 48 hours. Vital signs, subjective effects, and performance measure were collected. THC and MPH showed additive effects on heart rate and rate pressure product (e.g., peak heart rate for 10 mg THC + 0 mg, 10 mg, and 40 mg MPH = 89.1, 95.9, 102.0 beats/min, respectively). Main effects of THC and MPH were also observed on a range of subjective measures of drug effects, and significant THC dose × MPH dose interactions were found on measures of “Feel Drug,” “Good Effects,” and “Take Drug Again.” THC increased commission errors on a continuous performance test (CPT) and MPH reduced reaction time variability on this measure. Effects of THC, MPH, and their combination were variable on a measure of working memory (n-back task), though in general, MPH decreased reaction times and THC mitigated these effects. These results suggest that the combination of low to moderate doses of MPH and THC produces unique effects on cardiovascular function, subjective effects and performance measures.

Keywords

Methylphenidate; Prescription stimulant; Cannabis; Delta-9-tetrahydrocannabinol (THC)

1. Introduction

Methylphenidate (MPH) is considered a front-line treatment for the clinical management of attention deficit hyperactivity disorder (ADHD) (Pliszka et al., 2006). Although hundreds of studies have documented the efficacy of MPH for treating ADHD (Faraone, Biederman, & Roe, 2002; Faraone & Buitelaar, 2010; Faraone, Spencer, Alardi, Pagano, & Biederman, 2004), significant increases in prescription rates of MPH over the last 15 years have led to controversy about abuse, misuse, and diversion of the drug (Robison, Sclar, Skaer, & Galin, 1999; Safer, Zito, & Fine, 1996; Sembower, Ertischek, Buchholtz, Dasgupta, & Schnoll, 2013; Visser, Blumberg, Danielson, Bitsko, & Kogan, 2013; Visser et al., 2014; Zito et al., 2000; Zosel, Bartelson, Bailey, Lowenstein, & Dart, 2013).

Prevalence of prescribed stimulant misuse is highest among individuals between 12 and 25 years of age, ranging from 0.9% to 10.0% across studies. A number of studies report that stimulant diversion is a common problem, even among children as young as 6th grade (Johnston, O'Malley, Bachman, & Schulenberg, 2006; Kroutil et al., 2006; McCabe, Boyd, & Young, 2007; McCabe, Knight, Teter, & Wechsler, 2005; McCabe, Teter, & Boyd, 2004; McCabe, Teter, & Boyd, 2006; McCabe & West, 2013; Poulin, 2001).

Illicit users of prescription stimulants, including MPH, have higher rates of other drug and alcohol use, including cannabis (Barrett, Darredeau, Bordy, & Pihl, 2005; Low & Gendaszek, 2002; McCabe, Cranford, & Boyd, 2006; McCabe, Cranford, Morales, & Young, 2006; McCabe & West, 2013; McCabe et al., 2004, 2005, 2007; Poulin, 2001; Teter, McCabe, Cranford, Boyd, & Guthrie, 2005; Wilens, Gignac, Swezey, Monuteaux, & Biederman, 2006; Williams, Goodale, Shay-Fiddler, Gloster, & Chang, 2004). Most studies, however, have not differentiated between *concurrent* use (use of more than one drug within some specified time period; e.g., past 12 months) and *simultaneous* use (co-ingestion of more than one drug at the same time) (Martin, Clifford, & Clapper, 1992; Massello & Carpenter, 1999; Schensul, Convey, & Burkholder, 2005). Those studies that have assessed simultaneous substance use among illicit prescription stimulant users, suggest that it is very common for these drugs to be used in combination with marijuana; one study found that 52% of undergraduate illicit MPH users reported simultaneous use with marijuana (Barrett, Darredeau, & Pihl, 2006).

Both MPH and oral formulations of delta-9-tetrahydrocannabinol (THC) – the primary psychoactive component of smoked marijuana – result in robust cardiovascular (Hart, Haney, Vosburg, Comer, & Foltin, 2005; Kollins & Rush, 1999; Rush, Essman, Simpson, & Baker, 2001; Rush, Kollins, & Pazzaglia, 1998), subjective (Hart et al., 2002, 2005; Rush et al., 1998, 2001), and performance effects (Coghill et al., 2013; Curran, Brignell, Fletcher, Middleton, & Henry, 2002; Hammerness, Fried, Petty, Meller, & Biederman, 2013; Lane, Cherek, Tcheremissine, Lieving, & Pietras, 2005; Linssen, Sambeth, Vuurman, & Riedel, 2014; McDonald, Schleifer, Richards, & de Wit, 2003; Nandam et al., 2011; Ramaekers et

al., 2006). Although several studies have examined the interactive effects of smoked marijuana administered in combination with other stimulant-like drugs (e.g., cocaine, nicotine) (Foltin & Fischman, 1990; Penetar et al., 2005), no studies to date have explicitly examined the effects of MPH and THC co-administration.

The effects of simultaneous MPH and marijuana use may differ from the effects of either drug alone. Both MPH and marijuana, for instance, increase heart rate and blood pressure when administered acutely, even with oral formulations of delta-9-tetrahydrocannabinol (THC) (Hart et al., 2005; Kollins & Rush, 1999; Rush et al., 1998, 2001). With respect to subjective drug effects, both MPH and oral THC acutely increase ratings of “good effects,” “like drug,” and “like to take again” (Hart et al., 2002, 2005; Rush et al., 1998, 2001). In addition to physiological and subjective effects, MPH-THC co-administration may result in unique behavioral effects compared with the acute effects of each drug. THC administered alone either orally or in smoked form has been shown to disrupt a range of neurocognitive endpoints, including decision making (Lane et al., 2005), inhibitory control (McDonald et al., 2003; Ramaekers et al., 2006), and memory (Curran et al., 2002); though these effects have not been categorically replicated (Vadhan et al., 2007). By contrast, MPH has been shown to *improve* a range of neurocognitive endpoints, including inhibitory control and memory in individuals with and without ADHD (Coghill et al., 2013; Hammerness et al., 2013; Linssen et al., 2014; Nandam et al., 2011). It is not known whether the simultaneous use of THC and MPH results in additive effects on cardiovascular function and/or subjective effects; or whether MPH would serve to mitigate the performance impairing effects of marijuana.

Given the reported rates of simultaneous use of MPH and marijuana (Barrett et al., 2005, 2006), characterizing the effects of these specific drugs in combination is important to more fully evaluate the potential risks of co-administration. The primary objective of the present study therefore was to assess the effects of orally administered THC (dronabinol) alone (0 mg vs. 10 mg) and in combination with two doses of immediate release methylphenidate (0 mg, 10 mg, 40 mg) in a blinded fashion on measures of cardiovascular function (heart rate, blood pressure), subjective drug effects, and cognitive function (inhibitory control, attention, and working memory).

Given the exploratory nature of this study, we elected to use orally administered THC since it was more practical to administer in the context of a human laboratory study. Orally administered THC has been shown to have similar subjective and cardiovascular effects as smoked marijuana; and produces dose-dependent increases in plasma THC levels (Chait & Zacny, 1992; Hart et al., 2002; Wachtel, ElSohly, Ross, Ambre, & de Wit, 2002) and we therefore reasoned that an oral THC would be a safe and practical approach for an initial investigation of the combined effects of MPH and THC.

2. Methods

2.1. Subjects

Sixteen subjects (10 males, 6 females) with a history of recreational marijuana use participated in the study after providing informed consent approved by the local Institutional

Review Board. All subjects underwent a physical examination by a licensed physician, and medical and developmental histories were obtained. Current and previous drug use, including alcohol and cigarettes, were also measured at screening. To participate in the study, subjects were required to be between the ages of 18–45 years (mean age = 24.6 years), inclusive; have a body mass index >18 but <35; and report at least 10 lifetime uses of marijuana, including at least once in the past 2 months. All participants reported more than 40 lifetime uses of marijuana, smoked for the first time at age 16.6 years, and reported smoking an average of 4 times in the past 30 days. A total of 12/16 participants report lifetime cigarette smoking, with 8/16 reporting cigarette smoking in the past 30 days. Participants reported an average of 7 times using alcohol in the past 30 days. Other than marijuana, the majority of participants reported no other illicit drug use in their lifetime, although several reported using inhalants (n = 2); cocaine (n = 3); ecstasy (n = 1); prescription stimulants (n = 2); and prescription pain medicine (n = 2).

Subjects were excluded if they met criteria for any *DSM-IV* diagnosis [assessed using the Structured Clinical Interview for *DSM-IV* (First, Gibbon, Williams, & Spitzer, 1997)]; reported a history of adverse reaction to stimulant medication; had a resting heart rate of >100 beats/minute or a systolic blood pressure >150 mm/Hg; reported a history of any significant medical problems (e.g., seizures, cardiac abnormalities, etc.); were currently prescribed any psychoactive medications; had an estimated IQ of <80 [assessed using the Kauffmann Brief Intelligence Scale (Kaufman & Kaufman, 2004)]; scored 6 on the Marijuana Screening Inventory [MSI-X; (Alexander & Leung, 2006)]; or scored 8 on the Alcohol Use Disorders Identification Test [AUDIT; (Bohn, Babor, & Kranzler, 1995)].

2.2. General procedures

All study procedures were reviewed and approved by the local institutional review board. All subjects provided informed consent for the study and, following a Screening session, completed 6 experimental sessions. Subjects were told that the purpose of the study was to measure the effects of stimulant drugs (methylphenidate and/or amphetamine) alone and/or in combination with THC (dronabinol) on mood, cardiovascular functioning, and behavior. Subjects were told that they could receive methylphenidate, amphetamine, dronabinol, and placebo in any combination. Other than receiving this general information, participants were unaware of the type of drug administered. Following the study, subjects were informed specifically which drugs they had received.

Subjects arrived at the laboratory between 0700 and 0900 on the morning of each scheduled experimental session. Subjects were transported to and from the laboratory by taxi. Subjects provided urine samples each day that were screened for excluded drugs using InstaCup Drug Screens (Columbia Laboratory Supplies). Breath alcohol levels were assessed each morning with a handheld breathalyzer (ALERT model; Columbia Laboratory Supplies) and participants were required to record a BAL of 0.0. No subjects were excluded for noncompliance with drug and alcohol requirements. Subjects also had to pass a field sobriety test to participate in the session for that day. Following arrival, subjective effects measures and vital signs were assessed. Approximately 30 minutes after arrival, THC capsules were administered (0 mg or 10 mg). Ninety minutes later, MPH capsules were

administered (0 mg, 10 mg, or 40 mg). The timing of dosing was designed such that peak effects of methylphenidate occurred at comparable times as peak effects of THC – peak effects of oral THC occur approximately 3 hours post-dose, whereas MPH peak effects occur approximately 1.5 hours after dosing.

Throughout the session, vital signs and subjective effects were assessed every 30 minutes. Performance measures were administered 4 hours following THC administration (2.5 hours following MPH administration). The last assessment point was 6.5 hours following THC administration, after which a field sobriety test was conducted and subjects were dismissed from the laboratory. Transportation was again provided via taxi for all subjects. When behavioral or physiological testing was not ongoing, subjects were allowed to participate in a variety of sedentary activities, such as reading/studying, watching television, playing video or card games or solving puzzles.

Behavioral testing was conducted in a separated sound-attenuated room located adjacent to the general laboratory area. The testing rooms consisted of a desk and chair, a PC computer and monitor, keyboard, computer mouse, and physiological monitoring equipment. The PC was used to record responses to all subject-rated measures using the mouse as the primary input device. Subjects were able to earn up to \$800 for completing all experimental sessions.

2.3. Dependent measures – vital signs

Heart rate and blood pressure were recorded using a Vital Check 4200 digital monitor (Ivac Corp., San Diego, CA). Physiological measures were recorded upon arrival to the laboratory, and every thirty minutes thereafter. Subjects who exhibited sustained (at 2 or more consecutive assessments) heart rate or systolic blood pressure above 100 beats/minute or 160 mm/Hg, respectively were evaluated by a physician to ensure safety. In addition to the measured heart rate and blood pressure parameters, rate-pressure product was calculated as the product of heart rate and systolic blood pressure. Rate-pressure product is considered to be an indicator of the oxygen requirements of the heart and is a measure of overall cardiac exertion. Vital signs and other adverse reactions were monitored throughout each session and a study physician (RD or AC) were available in the event of untoward events.

2.4. Dependent Measures – subject-rated effects

The Adjective Rating Scale (ARS) (Oliveto et al., 1992), the Addiction Research Center Inventory (ARCI) (Martin, Sloan, Sapira, & Jasinski, 1971), and the Drug-Effect Questionnaire (DEQ) (Rush et al., 2001; Stoops, Glaser, Fillmore, & Rush, 2004) were used to assess subjective effects. The ARS consists of 32 items and contains two 16-item subscales: Sedative and Stimulant. The Stimulant scale from the ARS has been shown to be sensitive to the effects of MPH in the dose range used in the present study (Rush et al., 2001). The ARCI is commonly used to assess abuse liability of a variety of drug classes and contains five major subscales: Morphine-Benzedrine Group (MBG; a measure of euphoria); Pentobarbital, Chlorpromazine, Alcohol Group (PCAG; a measure of sedation); Lysergic Acid Diethylamide (LSD; a measure of dysphoria); and Benzedrine Group and Amphetamine scales (BG, A; empirically derived stimulant sensitive scales). The DEQ consists of eleven 100 mm visual analog scales presented on the computer screen one at a

time. Subjects are instructed to rate each item on the basis of how they feel at the present time. Each visual analog scale was anchored with the descriptors “*not at all*,” “*some*,” and “*an awful lot*.” The DEQ items were: “I feel the medicine’s effect,” “I feel good effects of the medicine,” “I feel bad effects from the medicine,” “I like the medicine,” “I feel friendly,” “I feel confused,” “I can concentrate right now,” “I feel excited,” “I feel alert,” “I feel relaxed,” and “I would like to take this medicine again.” Subjects used the mouse to position a cross-line on the analog scale to indicate their response.

2.5. Dependent measures – performance measures

2.5.1. Conners Continuous Performance Test (CPT; (Conners, 1994))—The Conners Continuous Performance Test was completed on an IBM-compatible desktop computer. During this task, 360 total letters appeared on the computer screen, one at a time, each for approximately 250 milliseconds. The 360 trials were presented in 18 blocks of 20 trials each. The blocks differed only in the interstimulus intervals (ISI) between letter presentations, which lasted 1-, 2-, or 4-seconds. Subjects were instructed to press the spacebar when any letter except the letter “X” appeared on the screen. The event rate, or percentage of trials when letters other than “X” appeared, was 90% across all ISI blocks. Reaction time was measured from the point at which any letter other than “X” appeared on the screen until the spacebar was depressed. The Conners’ CPT task takes approximately 14 minutes to complete. Four primary outcome measures were used or data analysis: 1) omission errors (failure to respond to non-“X” targets; a measure of vigilance); 2) commission errors (responding to “X” targets; a measure of inhibitory control); 3) reaction time (time from presentation of a non-“X” target to response; a measure of psychomotor function; and 4) reaction time standard error (the variability of reaction time; a measure of attentional lapses).

2.5.2. n-Back task—A modified version of the n-back task was used (Mendrek et al., 2006). The task is a computer-administered test of working memory that takes approximately 10 minutes to complete. During the n-back task, participants see a series of letters of the alphabet presented on a screen at a rate of one letter per second. Participants are required to identify whether the current stimulus being presented on the screen is the same as the stimulus presented n-back. In the 1-back condition, participants identify whether the current letter is the same as the letter that preceded it (i.e., 1 letter back). In the 2-back condition, participants identify whether the current letter is the same as the letter presented 2 letters back. Similarly, in the 3-back condition, participants identify whether the current letter is the same as the letter presented 3 letters back. A ‘0-back’ condition in which subjects press a button whenever they see the letter ‘X’ presented is also administered. Each letter is presented for 400 ms followed by a 1600 ms inter-stimulus interval. Each n-back condition was presented in a 42-s block, followed by a 15-s fixation period and a 3-s instruction screen. In each block, 7 targets were presented (33%) and 14 non-targets (67%), for a total of 21 trials. Two blocks of each n-back condition were presented, making 8 blocks total. Primary outcomes from this task included the percentage of correct responses in each n-back condition (0, 1, 2, or 3), and reaction time for each condition.

2.6. Drug dose and administration

Across the 6 experimental sessions, subjects received, in random order, all combinations of 2 doses of THC (0 mg, 10 mg) and 3 doses of MPH (0 mg, 10 mg, 40 mg). Experimental sessions were scheduled a minimum of 48 hours apart. All drugs were administered under double-blind conditions and were prepared by a research pharmacy. Doses were prepared by encapsulating commercially available MPH hydrochloride or dronabinol and lactose filler. Placebo capsules contained only lactose. Medical oversight for the protocol was the responsibility of the study physicians. During each session, participants orally ingested capsules with 150 ml water. THC capsules were administered approximately 30 minutes following arrival at the laboratory and MPH capsules were administered 90 minutes following THC administration. Drug administration procedures were designed to ensure that participants swallowed the capsules and did not open them in their mouths and taste the contents (Abreu & Griffiths, 1996).

2.7. Data analysis

Analyses were conducted using Stata SE for Macintosh (Stata Corp., College Station, TX, USA). All data were analyzed using 2 (THC dose: 0 mg, 10 mg) \times 3 (MPH dose: 0 mg, 10 mg, 40 mg) repeated measures ANOVA. When main effects or interactions were observed, planned pairwise comparisons were conducted to test the additive effects of THC administration following MPH administration across doses. Specifically, 0 mg THC was compared to 10 mg THC across MPH dose levels and 0, 10, and 40 mg MPH were compared across the two THC dose levels. These comparisons were conducted using the Tukey HSD test. CPT and n-back data were analyzed with the outcome measures noted. For subjective effects and vital sign data, analyses were conducted in two ways. First, peak effects were analyzed, which were the highest values reported following drug administration for each day. Second, area-under-the-time-course-curve (AUC) analyses were conducted using the trapezoid method (Kollins & Rush, 2002). Since AUC and peak effects results were virtually identical with respect to the pattern of findings, only peak effects data are described in the results.

3. Results

3.1. Vital signs

In general, both drugs and their combination were well-tolerated across participants. One adverse event required the attention of the study physician – a male study participant experienced extended tachycardia (>100 bpm) following the combination of 40 mg MPH and 10 mg THC. The study physician monitored the participant and performed an ECG. The participant remained in the lab for several extra hours to ensure safety. Since this event occurred on his last study visit, he did not have to return for any additional study visits.

3.1.1. Heart Rate—Table 1 shows peak effects results for heart rate, systolic and diastolic blood pressure, and rate-pressure product. Both MPH and THC resulted in significant main effects on heart rate. In the absence of MPH (i.e., MPH placebo condition), there was no difference between the placebo and 10 mg THC conditions (84.3 vs. 89.1 bpm, respectively). In the absence of THC, 40 mg MPH resulted in significantly greater heart rate

compared to both the 10 mg MPH and 0 mg MPH conditions. The combination of 10 mg THC and both the 10 mg and 40 mg MPH doses resulted in significantly higher heart rate than either of these MPH conditions in combination with 0 mg THC. Finally, when administered in combination with 10 mg THC, 40 mg MPH resulted in significantly higher heart rate than 0 mg MPH.

3.1.2. Systolic and diastolic blood pressure—There was a significant main effect of MPH on both systolic and diastolic blood pressure characterized by an increase under the 40 mg dose of MPH. No other significant main effects or interactions were observed.

3.1.3. Rate pressure product—Significant main effects of both THC and MPH were observed for RPP. There was no difference between 10 mg THC and 0 mg THC in the absence of MPH. By contrast, the 40 mg dose of MPH resulted in significantly higher RPP compared to both the 10 mg MPH dose and the 0 mg MPH dose in the absence of THC. The 10 mg dose of THC resulted in significantly higher RPP than the 0 mg THC dose when administered in combination with both 10 and 40 mg MPH. When 40 mg MPH was administered in combination with 10 mg THC, RPP was higher than 10 mg.

3.2. Subjective effects

Table 2 illustrates peak effects for the ARS, ARCI, and DEQ. Fig. 2 shows results from several subscales across these 3 questionnaires on which main effects or interactions were observed. There were main effects for MPH on the following subscales: ARS Stimulant scale, ARCI MBG and A scales, DEQ Feel Drug, Good Effect, Bad Effect, Like Drug, Confused, Excited, and Take Again Scales. In general, the main effects of MPH across subjective effect scales were characterized by higher ratings for the 40 mg dose compared to the 10 mg or 0 mg doses. For example, on the ARS Stimulant subscale in the both THC conditions, the 40 mg MPH dose resulted in significantly higher ratings than the 10 mg or 0 mg MPH dose.

There were significant main effects of THC dose on the following subscales: ARS Sedative scale, ARCI PCAG and LSD scales, DEQ Feel Drug, Good Effects, Bad Effects, Like Drug, Confused, and Alert subscales. The main effects of THC were characterized in general by a pattern of elevated ratings under the 10 mg condition compared to the 0 mg condition, regardless of MPH dose.

Significant MPH \times THC interactions were observed on 3 of the DEQ scales: Feel Drug, Good Effects, and Take Drug Again (Fig. 2, Panels C–E). The interaction was characterized by dose-dependent increases in ratings of MPH effects under the THC 0 mg condition combined with comparatively higher and consistent ratings of 10 mg THC effects across doses of MPH.

3.3. Performance measures

Table 3 shows results from the CPT and n-back across drug conditions. For the CPT, no drug effects were observed for omission errors. There was a significant main effect of THC on commission errors that was generally characterized by a greater number of errors in the

10 mg condition compared to the 0 mg condition across MPH doses, although these specific contrasts were not significantly different. There was also a significant main effect of MPH on RT SE characterized by a general MPH-dose-dependent decrease in RT SE across both doses of THC.

On the n-back task, there were no main effects or interactions for correct responding under any of the conditions. There were main effects of MPH dose on RT in both the 0-back and 2-back conditions. Both of these effects were characterized by faster reaction times on 40 mg MPH compared to 10 mg MPH under 0 mg THC conditions. There was also a significant main effect of THC in the 3-back condition. In general, the 10 mg dose of THC resulted in slower reaction times than the 0 mg THC condition across doses of MPH.

4. Discussion

The present study is the first to systematically measure the effects of MPH administered in combination with THC in human participants. Several findings are noteworthy. First, there were significant additive effects of THC and MPH on heart rate. When administered with either 10 mg or 40 mg MPH, THC significantly increased heart rate more than the MPH doses alone. Second, additive and interactive effects of THC and MPH were observed across a range of subjective effects; however, most of these effects were largely due to robust effects of THC. Finally, the effects of THC and MPH alone and in combination on performance measures were inconsistent, a finding that is somewhat discrepant from previous studies of orally administered and smoked THC.

Especially since the simultaneous use of these drugs is likely to occur in the context of smoked marijuana, which is itself associated with increased risk for a range of adverse cardiac events (Mittleman, Lewis, Maclure, Sherwood, & Muller, 2001; Sidney, 2002), the additive effects of THC and MPH on heart rate and RPP observed in the present study are noteworthy. Moreover, there is controversy regarding the occurrence of adverse cardiac events in patients prescribed MPH for clinical purposes (Biederman, Spencer, Wilens, Prince, & Faraone, 2006; Nissen, 2006; Winterstein et al., 2012), although in general data do not support the role of the drug in increasing risk in patients without significant predisposing factors (Cooper et al., 2011; Habel et al., 2011; Olfson et al., 2012; Westover & Halm, 2012; Winterstein et al., 2007, 2012). Whether the additive effects of MPH and THC observed in the present study would be observed following administration of smoked marijuana is unknown. However, for young adults using MPH illicitly, data from the present study and the extant literature suggest that there may be risk in combining oral MPH with smoked marijuana. Future work should more thoroughly characterize interactive cardiac effects of smoked marijuana taken in combination with orally administered MPH.

Consistent with previous research, in the present study, both MPH and THC significantly increased subjective ratings of drug effects compared to placebo conditions. There were also statistically significant interactions between THC and MPH for “Feel Drug Effect,” “Good Effects,” and “Take Again.” Given the pattern of findings, though, these interactions appear to be the result of 10 mg THC producing robust subjective effects across MPH doses. There was little evidence that any combination of MPH and THC doses produced effects different

than THC alone. However, since both oral THC and MPH produce reinforcing effects in laboratory studies (Hart et al., 2002, 2005; Kollins, English, Robinson, Hallyburton, & Chrisman, 2009; Rush et al., 2001), future studies should explicitly examine the reinforcing effects of the combination of these drugs (including smoked marijuana) to more fully understand their synergistic abuse potential.

In the present study, oral THC increased commission errors on the CPT and MPH decreased reaction time variability. Effects of both drugs on n-back performance was inconsistent. Previous studies have reported that both oral THC and smoked marijuana decrease inhibitory control and increase risky decision-making. In one laboratory study, smoking a high concentration marijuana cigarette (3.58% THC), compared to a lower concentration marijuana cigarette or placebo, resulted in significantly more risky choices and less sensitivity to consequences (Lane et al., 2005; McDonald et al., 2003). Another study found that orally administered THC (7.5 mg and 15 mg), compared to placebo, produced significantly slower stop-signal reaction times, a putative measure of inhibitory control (McDonald et al., 2003). In the current study, although there were significant main effects of THC on CPT commission errors, there was significant variability on this particular measure, raising the possibility that there may be important individual differences that moderate THC effects on impulsive responding. THC-induced increases in commission errors were somewhat mitigated with administration of both 10 mg and 40 mg MPH. It is possible then, that the dose of MPH used in the present study were high enough to counteract the effects of a relatively low dose of THC. Future research should assess whether this same pattern of findings is observed across a broader range of THC and MPH doses. The effects of MPH on reaction time variability in the present study are consistent with a number of studies that have reported beneficial effects of stimulants on measures of this construct (Coghill et al., 2013).

The present study found no effects of MPH, THC, or their combination on accuracy on the n-back, a measure of working memory performance, although there were transient effects on reaction time during this task. Previous studies have documented the deleterious effects of THC/marijuana on working memory and other related processes (Ranganathan & D'Souza, 2006; Vadhan et al., 2007). However, most studies have examined only the effects of smoked or intravenous THC, and studies administering oral THC have failed to find effects on working memory (Curran et al., 2002)

The present findings need to be considered in light of several important limitations. First, the size and nature of the sample should be considered when generalizing outcomes. The number of participants precluded important subanalyses, such as differences by sex or race/ethnicity. Indeed previous studies have found differential effects of sex following co-administration of smoked marijuana and nicotine on cardiovascular outcomes (Penetar et al., 2005). Also, participants were screened for any Axis I psychopathology and, as such, individuals with ADHD were excluded. Given that some studies have shown differential patterns of stimulant drug effects in ADHD versus non-ADHD samples (Kollins et al., 2009), future work should evaluate whether co-administration of stimulants and THC results in similar effects in individuals with and without ADHD. This is particularly important given that adolescents and adults with ADHD are at increased risk for problematic cannabis

use (Charach, Yeung, Climans, & Lillie, 2011; Lee, Humphreys, Flory, Liu, & Glass, 2011; Molina et al., 2013) and information about the interactive effects of stimulant treatment with marijuana use is not well understood. Second, the dose ranges of both THC and MPH were relatively limited. Although the decision to evaluate the doses in the present study were guided based on safety considerations, assessment of a broader range of doses will help to more fully characterize the effects of MPH and THC co-administration. Third, since we only evaluated the performance measures at a single time point approximately 4 hours after THC administration and 2.5 hours after MPH administration, we may have missed the peak effects of one or both drugs across participants. This timing could have contributed to the relative lack/inconsistency of findings on performance measures. Future studies investigating the combination of these drugs would be well served to assess the time course of effects at multiple points. Fourth, participants were not explicitly instructed to refrain from food/caffeine on the mornings of sessions. Variability in food or caffeine intake across participants could have influenced the outcomes, and future work should standardize meals and caffeine intake prior to dosing. Finally, the generalizability of findings is limited by our use of the oral formulation of THC rather than smoked marijuana. Given the substantial pharmacokinetic differences between these two routes of administration, our findings should be interpreted cautiously, especially with respect to the potential cardiovascular effects of co-administration. For example, compared to oral administration, the maximum plasma concentrations of THC following smoked marijuana in occasional users has been shown to be 6-18 times higher (Bossong et al., 2009; Toennes, Ramaekers, Theunissen, Moeller, & Kauert, 2008) (Marinol package insert). Given the similarity in behavioral and subjective effects of oral THC vs. smoked marijuana, however (Chait & Zacny, 1992; Hart et al., 2002, 2005; Wachtel et al., 2002), the effects of oral THC and MPH are still of interest and provide an important first step in evaluating this often used drug combination. Still, future studies would be well served to evaluate the effects of smoked marijuana in combination with MPH, or other prescription stimulants, such as amphetamine.

In spite of these limitations, several conclusions can be drawn from the present study. First, co-administration of MPH and THC results in additive effects on heart rate and rate-pressure product. These increases in cardiovascular stress occur in combination with a slight, though statistically non-significant attenuation of THC-induced changes in inhibitory control (CPT commission errors). In addition, 10 mg THC produced robust subjective effects associated with drug liking. These data raise the possibility that the combination of prescription stimulants, such as MPH, and THC, especially in smoked form, may be a desirable “cocktail” for young adults seeking euphorogenic effects of marijuana without adversely impacting cognitive performance. However, this combination may come at the cost of increasing cardiovascular strain, which could increase risk.

Acknowledgments

Support for this work was provided, in part, by funding from the National Institute on Drug Abuse (R01DA017196; PI: Kollins).

References

- Abreu ME, Griffiths RR. Drug tasting may confound human drug discrimination studies. *Psychopharmacology*. 1996; 125(3):255–257. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8815961). [PubMed: 8815961]
- Alexander D, Leung P. The Marijuana Screening Inventory (MSI-X): concurrent, convergent and discriminant validity with multiple measures. *The American Journal of Drug and Alcohol Abuse*. 2006; 32(3):351–378. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16864468). [PubMed: 16864468]
- Barrett SP, Darredeau C, Bordy LE, Pihl RO. Characteristics of methylphenidate misuse in a university student sample. *Canadian Journal of Psychiatry*. 2005; 50(8):457–461. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16127963).
- Barrett SP, Darredeau C, Pihl RO. Patterns of simultaneous polysubstance use in drug using university students. *Human Psychopharmacology*. 2006; 21(4):255–263. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16783813). [PubMed: 16783813]
- Biederman J, Spencer TJ, Wilens TE, Prince JB, Faraone SV. Treatment of ADHD with stimulant medications: response to Nissen perspective in the New England Journal of Medicine. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2006; 45(10):1147–1150. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16840880). [PubMed: 16840880]
- Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. *Journal of Studies on Alcohol*. 1995; 56(4):423–432. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7674678). [PubMed: 7674678]
- Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Windhorst AD, et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. *Neuropsychopharmacology*. 2009; 34(3):759–766. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18754005). [PubMed: 18754005]
- Chait LD, Zacny JP. Reinforcing and subjective effects of oral delta 9-THC and smoked marijuana in humans. *Psychopharmacology*. 1992; 107(2–3):255–262. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1319601). [PubMed: 1319601]
- Charach A, Yeung E, Climans T, Lillie E. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2011; 50(1):9–21. <http://dx.doi.org/10.1016/j.jaac.2010.09.019>. [PubMed: 21156266]
- Coghill DR, Seth S, Pedrosa S, Usala T, Currie J, Gagliano A. Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: Evidence from a systematic review and a meta-analysis. *Biological Psychiatry*. 2013 <http://dx.doi.org/10.1016/j.biopsych.2013.10.005>.
- Conners CK. The Conners continuous performance test. 1994
- Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, et al. ADHD drugs and serious cardiovascular events in children and young adults. *The New England Journal of Medicine*. 2011; 365(20):1896–1904. <http://dx.doi.org/10.1056/NEJMoa1110212>. [PubMed: 22043968]
- Curran HV, Brignell C, Fletcher S, Middleton P, Henry J. Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. *Psychopharmacology*. 2002; 164(1):61–70. <http://dx.doi.org/10.1007/s00213-002-1169-0>. [PubMed: 12373420]
- Faraone SV, Biederman J, Roe C. Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. *Journal of Clinical Psychopharmacology*. 2002; 22(5):468–473. (Retrieved from, <http://www.ncbi.nlm.nih.gov/pubmed/12352269>). [PubMed: 12352269]

- Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. *European Child and Adolescent Psychiatry*. 2010; 19(4):353–364. <http://dx.doi.org/10.1007/s00787-009-0054-3>. [PubMed: 19763664]
- Faraone SV, Spencer T, Alvardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. *Journal of Clinical Psychopharmacology*. 2004; 24(1):24–29. <http://dx.doi.org/10.1097/01.jcp.0000108984.11879.95>. [PubMed: 14709943]
- First, MB.; Gibbon, M.; Williams, JBW.; Spitzer, RL. *SCID Screen Patient Questionnaire – Extended version*. North Tonawanda, NY: Multi-Health Systems, Inc.; 1997.
- Foltin RW, Fischman MW. The effects of combinations of intranasal cocaine, smoked marijuana, and task performance on heart rate and blood pressure. *Pharmacology Biochemistry and Behavior*. 1990; 36(2):311–315. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2162543).
- Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. *JAMA*. 2011; 306(24):2673–2683. <http://dx.doi.org/10.1001/jama.2011.1830>. [PubMed: 22161946]
- Hammerness P, Fried R, Petty C, Meller B, Biederman J. Assessment of cognitive domains during treatment with OROS methylphenidate in adolescents with ADHD. *Child Neuropsychology*. 2013 <http://dx.doi.org/10.1080/09297049.2013.790359>.
- Hart CL, Haney M, Vosburg SK, Comer SD, Foltin RW. Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure. *Psychopharmacology*. 2005; 181(2):237–243. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15830233). [PubMed: 15830233]
- Hart CL, Ward AS, Haney M, Comer SD, Foltin RW, Fischman MW. Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans. *Psychopharmacology*. 2002; 164(4):407–415. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12457271). [PubMed: 12457271]
- Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. *Monitoring the Future national survey results on drug use, 1975–2005. Volume II: College students and adults ages 19–45* (NIH Publication No. 06-5884). 2006
- Kaufman, AS.; Kaufman, NL. *Kaufman Brief Intelligence Test, Second Edition (KBIT-II)*. Circle Pines, MN: AGS Publishing; 2004.
- Kollins SH, English J, Robinson R, Hallyburton M, Chrisman AK. Reinforcing and subjective effects of methylphenidate in adults with and without attention deficit hyperactivity disorder (ADHD). *Psychopharmacology*. 2009; 204(1):73–83. <http://dx.doi.org/10.1007/s00213-008-1439-6>. [PubMed: 19104775]
- Kollins SH, Rush CR. Effects of training dose on the relationship between discriminative-stimulus and self-reported drug effects of d-amphetamine in humans. *Pharmacology Biochemistry and Behavior*. 1999; 64(2):319–326. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10515308).
- Kollins SH, Rush CR. Sensitization to the cardiovascular but not subject-rated effects of oral cocaine in humans. *Biological Psychiatry*. 2002; 51(2):143–150. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11822993). [PubMed: 11822993]
- Kroutil LA, Van Brunt DL, Herman-Stahl MA, Heller DC, Bray RM, Penne MA. Nonmedical use of prescription stimulants in the United States. *Drug and Alcohol Dependence*. 2006; 84(2):135–143. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16480836). [PubMed: 16480836]
- Lane SD, Cherek DR, Tcheremissine OV, Lieving LM, Pietras CJ. Acute marijuana effects on human risk taking. *Neuropsychopharmacology*. 2005; 30(4):800–809. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15775958). [PubMed: 15775958]
- Lee SS, Humphreys KL, Flory K, Liu R, Glass K. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic

- review. *Clinical Psychology Review*. 2011; 31(3):328–341. <http://dx.doi.org/10.1016/j.cpr.2011.01.006>. [PubMed: 21382538]
- Linssen AM, Sambeth A, Vuurman EF, Riedel WJ. Cognitive effects of methylphenidate in healthy volunteers: a review of single dose studies. *International Journal of Neuropsychopharmacology*. 2014;1–17. <http://dx.doi.org/10.1017/S1461145713001594>. [PubMed: 23953038]
- Low KG, Gendaszek AE. Illicit use of psychostimulants among college students: A preliminary study. *Psychology, Health & Medicine*. 2002; 7(3):283–287.
- Martin CS, Clifford PR, Clapper RL. Patterns and predictors of simultaneous and concurrent use of alcohol, tobacco, marijuana, and hallucinogens in first-year college students. *Journal of Substance Abuse*. 1992; 4(3):319–326. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1458048). [PubMed: 1458048]
- Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. *Clinical Pharmacology and Therapeutics*. 1971; 12:245–258. [PubMed: 5554941]
- Massello W III, Carpenter DA. A fatality due to the intranasal abuse of methylphenidate (Ritalin). *Journal of Forensic Sciences*. 1999; 44(1):220–221. [PubMed: 9987890]
- McCabe SE, Boyd CJ, Young A. Medical and nonmedical use of prescription drugs among secondary school students. *The Journal of Adolescent Health*. 2007; 40(1):76–83. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17185209). [PubMed: 17185209]
- McCabe SE, Cranford JA, Boyd CJ. The relationship between past-year drinking behaviors and nonmedical use of prescription drugs: prevalence of co-occurrence in a national sample. *Drug and Alcohol Dependence*. 2006; 84(3):281–288. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16621337). [PubMed: 16621337]
- McCabe SE, Cranford JA, Morales M, Young A. Simultaneous and concurrent polydrug use of alcohol and prescription drugs: prevalence, correlates, and consequences. *Journal of Studies on Alcohol*. 2006; 67(4):529–537. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16736072). [PubMed: 16736072]
- McCabe SE, Knight JR, Teter CJ, Wechsler H. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. *Addiction*. 2005; 100(1):96–106. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15598197). [PubMed: 15598197]
- McCabe SE, Teter CJ, Boyd CJ. The use, misuse and diversion of prescription stimulants among middle and high school students. *Substance Use and Misuse*. 2004; 39(7):1095–1116. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15387205). [PubMed: 15387205]
- McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use and diversion of prescription stimulant medication. *Journal of Psychoactive Drugs*. 2006; 38(1):43–56. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16681175). [PubMed: 16681175]
- McCabe SE, West BT. Medical and nonmedical use of prescription stimulants: results from a national multicohort study. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2013; 52(12):1272–1280. <http://dx.doi.org/10.1016/j.jaac.2013.09.005>. [PubMed: 24290460]
- McDonald J, Schleifer L, Richards JB, de Wit H. Effects of THC on behavioral measures of impulsivity in humans. *Neuropsychopharmacology*. 2003; 28(7):1356–1365. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12784123). [PubMed: 12784123]
- Mendrek A, Monterosso J, Simon SL, Jarvik M, Brody A, Olmstead R, et al. Working memory in cigarette smokers: comparison to non-smokers and effects of abstinence. *Addictive Behaviors*. 2006; 31(5):833–844. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16009504). [PubMed: 16009504]
- Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. *Circulation*. 2001; 103(23):2805–2809. (Retrieved from, <http://www.ncbi.nlm.nih.gov/>

[entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11401936](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11401936)). [PubMed: 11401936]

- Molina BS, Hinshaw SP, Eugene Arnold L, Swanson JM, Pelham WE, Hechtman L, et al. Adolescent substance use in the multimodal treatment study of Attention-Deficit/Hyperactivity Disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2013; 52(3):250–263. <http://dx.doi.org/10.1016/j.jaac.2012.12.014>. [PubMed: 23452682]
- Nandam LS, Hester R, Wagner J, Cummins TD, Garner K, Dean AJ, et al. Methylphenidate but not atomoxetine or citalopram modulates inhibitory control and response time variability. *Biological Psychiatry*. 2011; 69(9):902–904. <http://dx.doi.org/10.1016/j.biopsych.2010.11.014>. [PubMed: 21193172]
- Nissen SE. ADHD drugs and cardiovascular risk. *The New England Journal of Medicine*. 2006; 354(14):1445–1448. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16549404). [PubMed: 16549404]
- Olfson M, Huang C, Gerhard T, Winterstein AG, Crystal S, Allison PD, et al. Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2012; 51(2):147–156. <http://dx.doi.org/10.1016/j.jaac.2011.11.008>. [PubMed: 22265361]
- Oliveto AH, Bickel WK, Hughes JR, Shea PJ, Higgins ST, Fenwick JW. Caffeine drug discrimination in humans: acquisition, specificity and correlation with self-reports. *The Journal of Pharmacology and Experimental Therapeutics*. 1992; 261(3):885–894. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1602393). [PubMed: 1602393]
- Penetar DM, Kouri EM, Gross MM, McCarthy EM, Rhee CK, Peters EN, et al. Transdermal nicotine alters some of marijuana's effects in male and female volunteers. *Drug and Alcohol Dependence*. 2005; 79(2):211–223. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16002030). [PubMed: 16002030]
- Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2006; 45(6):642–657. <http://dx.doi.org/10.1097/01.chi.0000215326.51175.eb>. [PubMed: 16721314]
- Poulin C. Medical and nonmedical stimulant use among adolescents: from sanctioned to unsanctioned use. *CMAJ: Canadian Medical Association Journal = Journal De l'Association Medicale Canadienne*. 2001; 165(8):1039–1044. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11699699).
- Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, Moeller MR. High-potency marijuana impairs executive function and inhibitory motor control. *Neuropsychopharmacology*. 2006; 31(10):2296–2303. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16572123). [PubMed: 16572123]
- Ranganathan M, D'Souza DC. The acute effects of cannabinoids on memory in humans: a review. *Psychopharmacology*. 2006; 188(4):425–444. <http://dx.doi.org/10.1007/s00213-006-0508-y>. [PubMed: 17019571]
- Robison LM, Sclar DA, Skaer TL, Galin RS. National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990–1995. *Clinical Pediatrics*. 1999; 38(4):209–217. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10326176). [PubMed: 10326176]
- Rush CR, Essman WD, Simpson CA, Baker RW. Reinforcing and subject-rated effects of methylphenidate and d-amphetamine in non-drug-abusing humans. *Journal of Clinical Psychopharmacology*. 2001; 21(3):273–286. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11386490). [PubMed: 11386490]

- Rush CR, Kollins SH, Pazzaglia PJ. Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans. *Experimental and Clinical Psychopharmacology*. 1998; 6(1):32–44. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9526144). [PubMed: 9526144]
- Safer DJ, Zito JM, Fine EM. Increased methylphenidate usage for attention deficit disorder in the 1990s. *Pediatrics*. 1996; 98(6 Pt 1):1084–1088. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8951257). [PubMed: 8951257]
- Schensul JJ, Convey M, Burkholder G. Challenges in measuring concurrency, agency and intentionality in polydrug research. *Addictive Behaviors*. 2005; 30(3):571–574. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15718073). [PubMed: 15718073]
- Sembower MA, Ertischek MD, Buchholtz C, Dasgupta N, Schnoll SH. Surveillance of diversion and nonmedical use of extended-release prescription amphetamine and oral methylphenidate in the United States. *Journal of Addictive Diseases*. 2013; 32(1):26–38. <http://dx.doi.org/10.1080/10550887.2012.759880>. [PubMed: 23480245]
- Sidney S. Cardiovascular consequences of marijuana use. *Journal of Clinical Pharmacology*. 2002; 42(11 Suppl.):64S–70S. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12412838). [PubMed: 12412838]
- Stoops WW, Glaser PE, Fillmore MT, Rush CR. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. *Journal of Psychopharmacology*. 2004; 18(4):534–543. <http://dx.doi.org/10.1177/0269881104047281>. [PubMed: 15582920]
- Teter CJ, McCabe SE, Cranford JA, Boyd CJ, Guthrie SK. Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. *Journal of American College Health*. 2005; 53(6):253–262. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15900989). [PubMed: 15900989]
- Toennes SW, Ramaekers JG, Theunissen EL, Moeller MR, Kauert GF. Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint. *Journal of Analytical Toxicology*. 2008; 32(7):470–477. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18713514). [PubMed: 18713514]
- Vadhan NP, Hart CL, van Gorp WG, Gunderson EW, Haney M, Foltin RW. Acute effects of smoked marijuana on decision making, as assessed by a modified gambling task, in experienced marijuana users. *Journal of Clinical and Experimental Neuropsychology*. 2007; 29(4):357–364. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17497559). [PubMed: 17497559]
- Visser SN, Blumberg SJ, Danielson ML, Bitsko RH, Kogan MD. State-based and demographic variation in parent-reported medication rates for attention-deficit/hyperactivity disorder, 2007–2008. *Preventing Chronic Disease*. 2013; 10:E09. <http://dx.doi.org/10.5888/pcd9.120073>. [PubMed: 23347704]
- Visser SN, Danielson ML, Bitsko RH, Holbrook JR, Kogan MD, Ghandour RM, et al. Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003–2011. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2014; 53(1):34–46. e2. <http://dx.doi.org/10.1016/j.jaac.2013.09.001>. [PubMed: 24342384]
- Wachtel SR, ElSohly MA, Ross SA, Ambre J, de Wit H. Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans. *Psychopharmacology*. 2002; 161(4):331–339. <http://dx.doi.org/10.1007/s00213-002-1033-2>. [PubMed: 12073159]
- Westover AN, Halm EA. Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review. *BMC Cardiovascular Disorders*. 2012; 12:41. <http://dx.doi.org/10.1186/1471-2261-12-41>. [PubMed: 22682429]
- Wilens TE, Gignac M, Swezey A, Monuteaux MC, Biederman J. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. *Journal of the*

- American Academy of Child and Adolescent Psychiatry. 2006; 45(4):408–414. <http://dx.doi.org/10.1097/01.chi.0000199027.68828.b3> (S0890-8567(09)62060-8 [pii]). [PubMed: 16601645]
- Williams RJ, Goodale LA, Shay-Fiddler MA, Gloster SP, Chang SY. Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents. *The American Journal on Addictions*. 2004; 13(4):381–389. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15370936). [PubMed: 15370936]
- Winterstein AG, Gerhard T, Kubilis P, Saidi A, Linden S, Crystal S, et al. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. *BMJ*. 2012; 345:e4627. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=22809800). [PubMed: 22809800]
- Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. *Pediatrics*. 2007; 120(6):e1494–e1501. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18055666). [PubMed: 18055666]
- Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. *JAMA*. 2000; 283(8):1025–1030. (Retrieved from, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10697062). [PubMed: 10697062]
- Zosel A, Bartelson BB, Bailey E, Lowenstein S, Dart R. Characterization of adolescent prescription drug abuse and misuse using the Researched Abuse Diversion and Addiction-related Surveillance (RADARS((R))) System. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2013; 52(2):196–204. e2. <http://dx.doi.org/10.1016/j.jaac.2012.11.014>. [PubMed: 23357446]

Table 1

Mean peak effects (SD) for vital signs across dose levels of MPH and THC.

Peak Effects	MPH Dose						THC × MPH F
	0 mg		10 mg		40 mg		
	0 mg THC	10 mg THC	0 mg THC	10 mg THC	0 mg THC	10 mg THC	
Heart Rate	84.3 (10.6)	89.1 (8.3)	83.6 (11.8)	95.9 (10.1)	95.3 (15.4)	102.0 (18.1)	26.73** 14.39** 1.32
Systolic BP	136.1 (13.2)	139.1 (16.9)	137.3 (9.8)	136.1 (15.8)	142.3 (15.3)	145.1 (17.1)	0.41 4.79* 0.91
Diastolic BP	83 (5.9)	85.9 (11.8)	83.5 (8.0)	83.1 (5.6)	87.5 (11.2)	88.1 (9.7)	0.4 4.49* 0.5
Rate pressure product	11441.8 (1584.1)	12352.0 (1610.5)	11425.5 (1478.6)	13031.1 (1847.0)	13461.1 (2025.5)	14845.8 (3429.0)	10.7** 16.45** 0.19

Right columns indicate F-values for 2 factor repeated measures ANOVA.

* p < 0.05,

** p < 0.01.

Table 2

Mean peak effects(SD)for subjective effects measures across dose levels of MPH and THC.

ARS peak effects	MPH Dose						THC F	MPHF	THC × MPHF
	0 mg		10 mg		40 mg				
	0 mg THC	10 mg THC	0 mg THC	10 mg THC	0 mg THC	10 mg THC			
Stimulant subscale	26.3 (3.7)	27.1 (4.6)	27.4 (5.0)	27.4 (5.9)	32.0 (7.3)	32.2 (5.8)	0.00	7.61**	0.01
Sedative subscale	27.3 (8.4)	30.5 (7.6)	23.8 (6.7)	30.9 (10.8)	24.6 (5.2)	29.8 (8.7)	11.35**	0.47	2.58
ARCI peak effects									
PCAG	6.0 (3.6)	8.3 (3.8)	4.6 (2.6)	8.1 (3.9)	5.3 (2.9)	8.7 (3.8)	36.74**	0.71	1.47
BG	5.1 (2.1)	5.9 (2.3)	6.3 (2.7)	6.1 (3.1)	7.4 (2.8)	6.6 (2.2)	0.00	5.12*	2.70
LSD	4.9 (2.0)	5.8 (2.3)	4.2 (2.3)	5.8 (3.0)	5.1 (2.7)	6.8 (2.4)	22.18**	2.47	1.00
MBG	7.0 (4.5)	9.9 (5.6)	9.3 (6.4)	10.6 (6.9)	11.5 (6.2)	12.3 (4.9)	3.69	7.64**	0.74
A	3.3 (2.5)	4.5 (2.9)	4.3 (3.0)	4.6 (2.8)	5.5 (2.7)	5.6 (2.4)	2.07	6.51**	0.72
DEQ peak effects									
Feel drug effect	35.9 (32.3)	78.5 (17.3)	47.9 (32.1)	75.8 (21.3)	75.3 (24.5)	82.7 (16.5)	35.44**	10.71**	5.87**
Good effect	34.9 (28.6)	68.9 (14.0)	55.6 (28.6)	68.3 (24.3)	67.9 (21.9)	78.8 (16.5)	26.35**	9.59**	4.62*
Bad effect	19.6 (22.9)	41.9 (22.2)	22.3 (24.1)	28.3 (25.7)	36.1 (29.3)	47.6 (29.9)	9.10**	7.64**	2.68
Like drug	55.6 (13.6)	67.7 (15.2)	58.1 (22.1)	66.8 (20.5)	68.4 (17.9)	73.1 (15.9)	8.94**	6.50**	0.87
Friendly	72.8 (17.3)	70.7 (16.3)	68.8 (15.4)	75.1 (18.5)	76.5 (17.0)	74.9 (16.6)	0.04	1.40	1.61
Confused	18.6 (22.8)	34.7 (27.8)	16.9 (22.6)	32.6 (27.1)	29.3 (31.0)	41.7 (31.6)	13.15**	6.21**	0.05
Concentrate	77.8 (17.9)	74.8 (14.9)	76.1 (18.1)	73.9 (17.7)	81.4 (17.5)	77.4 (15.2)	3.99	2.01	0.04
Excited	51.6 (23.1)	52.1 (21.6)	51.6 (26.2)	52.3 (25.7)	63.8 (22.2)	67.2 (22.2)	0.33	7.15**	0.09
Alert	71.5 (19.2)	71.7 (14.6)	79.2 (15.8)	71.9 (19.3)	81.9 (14.1)	77.7 (13.8)	5.04*	2.53	0.77
Relaxed	76.4 (16.7)	75.5 (13.0)	73.6 (16.1)	81.8 (15.3)	76.1 (17.3)	79.4 (16.5)	1.15	0.38	1.35
Take drug	57.6 (23.3)	65.2 (19.4)	54.8 (25.0)	67.2 (21.0)	71.9 (18.4)	71.3 (19.0)	3.92	4.72*	4.57*

Right columns indicate F-values for 2 factor repeated measures ANOVA.

* p < 0.05,

**
p < 0.01

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Table 3
 CPT and n-Back performance measures [mean (SD)] across dose levels of MPH and THC.

CPT	MPH dose						THC × MPH F		
	0 mg		10 mg		40 mg				
	0 mg THC	10 mg THC	0 mg THC	10 mg THC	0 mg THC	10 mg THC			
Omission errors (#)	3.2 (4.8)	5.3 (8.9)	1.4 (1.5)	1.9 (4.4)	1.3 (2.6)	3.9 (6.7)	2.11	2.61	0.6
Commission errors (#)	10.0 (9.2)	14.0 (7.4)	10.5 (7.3)	11.0 (7.9)	10.3 (10.1)	12.5 (9.9)	5.37*	0.52	0.58
Reaction time (ms)	349.3 (109.1)	335.6 (99.7)	338.7 (99.2)	330.2 (99.0)	354.0 (49.1)	332.5 (108.7)	0.61	0.32	0.07
Reaction time SE (ms)	6.2 (3.2)	8.6 (7.9)	5.8 (2.8)	4.9 (2.1)	4.5 (1.8)	5.8 (4.2)	1.03	7.18**	1.34
n-Back % correct									
0-back	0.99 (0.03)	0.98 (0.04)	0.98 (0.05)	1.0 (0.02)	0.99 (0.03)	1.0 (0.0)	0.03	1.46	2.03
1-back	0.99 (0.02)	0.96 (0.11)	0.94 (0.13)	0.98 (0.04)	0.98 (0.04)	0.96 (0.11)	0.08	0.11	1.9
2-back	0.88 (0.19)	0.87 (0.19)	0.82 (0.22)	0.85 (0.23)	0.86 (0.22)	0.95 (0.10)	0.04	1.64	0.92
3-back	0.80 (0.25)	0.73 (0.27)	0.72 (0.26)	0.79 (0.27)	0.76 (0.25)	0.77 (0.26)	1.42	0.07	3.33
n-Back reaction time (ms)									
0-back	446.0 (57.6)	442.9 (61.8)	488.8 (84.4)	464.6 (65.1)	427.4 (65.7)	421.2 (36.4)	0.73	7.50**	0.47
1-back	457.7 (82.4)	493.3 (96.2)	465.5 (89.0)	460.8 (75.9)	424.5 (65.5)	451.6 (93.4)	3.51	2.46	0.86
2-back	552.9 (155.8)	577.6 (120.3)	575.2 (150.5)	552.8 (153.2)	477.5 (90.4)	499.7 (116.3)	0.23	4.40*	0.85
3-back	611.0 (115.1)	674.1 (180.5)	596.4 (125.1)	631.6 (178.7)	526.5 (103.1)	600.4 (127.4)	5.98*	2.62	0.33

Right columns indicate F-values for 2 factor repeated measures ANOVA.

* p < 0.05,

** p < 0.01.